{
  "symbol": "ABBV",
  "year": 2024,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.3112,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.054
  },
  "top_positive": [
    {
      "sent": "Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 United States $ 9,041 $ 9,201 (1.7) % (1.7) % International 3,269 3,024 8.1 % 11.6 % Net revenues $ 12,310 $ 12,225 0.7 % 1.6 % 2024 Form 10-Q | 31 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Immunology Humira United States $ 1,771 $ 2,948 (39.9) % (39.9) % International 499 593 (15.8) % (11.6) % Total $ 2,270 $ 3,541 (35.9) % (35.2) % Skyrizi United States $ 1,656 $ 1,139 45.3 % 45.3 % International 352 221 59.4 % 61.6 % Total $ 2,008 $ 1,360 47.6 % 48.0 % Rinvoq United States $ 725 $ 449 61.4 % 61.4 % International 368 237 55.3 % 62.8 % Total $ 1,093 $ 686 59.3 % 61.9 % Oncology Imbruvica United States $ 610 $ 638 (4.3) % (4.3) % Collaboration revenues 228 240 (5.1) % (5.1) % Total $ 838 $ 878 (4.5) % (4.5) % Venclexta United States $ 281 $ 265 6.2 % 6.2 % International 333 273 21.9 % 26.1 % Total $ 614 $ 538 14.2 % 16.3 % Elahere (a) United States $ 64 $ \u2014 n/m n/m Epkinly Collaboration revenues $ 22 $ \u2014 n/m n/m International 5 \u2014 n/m n/m Total $ 27 $ \u2014 n/m n/m Aesthetics Botox Cosmetic United States $ 389 $ 409 (4.9) % (4.9) % International 244 250 (2.2) % 1.2 % Total $ 633 $ 659 (3.9) % (2.6) % Juvederm Collection United States $ 106 $ 122 (13.2) % (13.2) % International 191 233 (18.1) % (14.0) % Total $ 297 $ 355 (16.4) % (13.7) % Other Aesthetics United States $ 281 $ 246 13.7 % 13.7 % International 38 40 (3.7) % 1.2 % Total $ 319 $ 286 11.3 % 12.0 % Neuroscience Botox Therapeutic United States $ 611 $ 587 4.1 % 4.1 % International 137 132 3.9 % 6.3 % Total $ 748 $ 719 4.1 % 4.5 % Vraylar United States $ 692 $ 560 23.5 % 23.5 % International 2 1 >100.0 % >100.0 % Total $ 694 $ 561 23.6 % 23.6 % Duodopa United States $ 25 $ 25 (2.6) % (2.6) % International 90 93 (2.7) % (3.7) % Total $ 115 $ 118 (2.7) % (3.5) % Ubrelvy United States $ 197 $ 150 31.5 % 31.5 % International 6 2 >100.0 % >100.0 % Total $ 203 $ 152 33.8 % 33.8 % Qulipta United States $ 128 $ 66 94.5 % 94.5 % International 3 \u2014 >100.0 % >100.0 % Total $ 131 $ 66 97.7 % 97.7 % 2024 Form 10-Q | 32 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Other Neuroscience United States $ 61 $ 75 (18.5) % (18.5) % International 13 4 >100.0 % >100.0 % Total $ 74 $ 79 (6.9) % (6.7) % Eye Care Ozurdex United States $ 34 $ 39 (13.7) % (13.7) % International 97 76 27.9 % 29.3 % Total $ 131 $ 115 13.7 % 14.6 % Lumigan/Ganfort United States $ 29 $ 63 (55.0) % (55.0) % International 62 67 (7.6) % (6.4) % Total $ 91 $ 130 (30.5) % (29.9) % Alphagan/Combigan United States $ 15 $ 28 (47.0) % (47.0) % International 44 43 1.9 % 6.9 % Total $ 59 $ 71 (17.7) % (14.7) % Restasis United States $ 44 $ 79 (44.1) % (44.1) % International 13 13 (1.4) % 4.1 % Total $ 57 $ 92 (38.1) % (37.3) % Other Eye Care United States $ 105 $ 110 (4.8) % (4.8) % International 95 90 5.9 % 9.3 % Total $ 200 $ 200 \u2014 % 1.5 % Other Key Products Mavyret United States $ 144 $ 171 (15.8) % (15.8) % International 205 193 6.2 % 9.0 % Total $ 349 $ 364 (4.1) % (2.6) % Creon United States $ 285 $ 305 (6.6) % (6.6) % Linzess/Constella United States $ 257 $ 251 2.5 % 2.5 % International 9 8 9.2 % 6.8 % Total $ 266 $ 259 2.8 % 2.7 % All other $ 744 $ 691 8.2 % 9.9 % Total net revenues $ 12,310 $ 12,225 0.7 % 1.6 % n/m \u2013 Not meaningful (a) Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.",
      "score": 0.9966
    },
    {
      "sent": "Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 United States $ 9,041 $ 9,201 (1.7) % (1.7) % International 3,269 3,024 8.1 % 11.6 % Net revenues $ 12,310 $ 12,225 0.7 % 1.6 % 2024 Form 10-Q | 31 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Immunology Humira United States $ 1,771 $ 2,948 (39.9) % (39.9) % International 499 593 (15.8) % (11.6) % Total $ 2,270 $ 3,541 (35.9) % (35.2) % Skyrizi United States $ 1,656 $ 1,139 45.3 % 45.3 % International 352 221 59.4 % 61.6 % Total $ 2,008 $ 1,360 47.6 % 48.0 % Rinvoq United States $ 725 $ 449 61.4 % 61.4 % International 368 237 55.3 % 62.8 % Total $ 1,093 $ 686 59.3 % 61.9 % Oncology Imbruvica United States $ 610 $ 638 (4.3) % (4.3) % Collaboration revenues 228 240 (5.1) % (5.1) % Total $ 838 $ 878 (4.5) % (4.5) % Venclexta United States $ 281 $ 265 6.2 % 6.2 % International 333 273 21.9 % 26.1 % Total $ 614 $ 538 14.2 % 16.3 % Elahere (a) United States $ 64 $ \u2014 n/m n/m Epkinly Collaboration revenues $ 22 $ \u2014 n/m n/m International 5 \u2014 n/m n/m Total $ 27 $ \u2014 n/m n/m Aesthetics Botox Cosmetic United States $ 389 $ 409 (4.9) % (4.9) % International 244 250 (2.2) % 1.2 % Total $ 633 $ 659 (3.9) % (2.6) % Juvederm Collection United States $ 106 $ 122 (13.2) % (13.2) % International 191 233 (18.1) % (14.0) % Total $ 297 $ 355 (16.4) % (13.7) % Other Aesthetics United States $ 281 $ 246 13.7 % 13.7 % International 38 40 (3.7) % 1.2 % Total $ 319 $ 286 11.3 % 12.0 % Neuroscience Botox Therapeutic United States $ 611 $ 587 4.1 % 4.1 % International 137 132 3.9 % 6.3 % Total $ 748 $ 719 4.1 % 4.5 % Vraylar United States $ 692 $ 560 23.5 % 23.5 % International 2 1 >100.0 % >100.0 % Total $ 694 $ 561 23.6 % 23.6 % Duodopa United States $ 25 $ 25 (2.6) % (2.6) % International 90 93 (2.7) % (3.7) % Total $ 115 $ 118 (2.7) % (3.5) % Ubrelvy United States $ 197 $ 150 31.5 % 31.5 % International 6 2 >100.0 % >100.0 % Total $ 203 $ 152 33.8 % 33.8 % Qulipta United States $ 128 $ 66 94.5 % 94.5 % International 3 \u2014 >100.0 % >100.0 % Total $ 131 $ 66 97.7 % 97.7 % 2024 Form 10-Q | 32 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Other Neuroscience United States $ 61 $ 75 (18.5) % (18.5) % International 13 4 >100.0 % >100.0 % Total $ 74 $ 79 (6.9) % (6.7) % Eye Care Ozurdex United States $ 34 $ 39 (13.7) % (13.7) % International 97 76 27.9 % 29.3 % Total $ 131 $ 115 13.7 % 14.6 % Lumigan/Ganfort United States $ 29 $ 63 (55.0) % (55.0) % International 62 67 (7.6) % (6.4\nofibrosis following evaluation of the totality of data from the Phase 3 TRANSFORM-1 trial and recent feedback from regulators.",
      "score": 0.9938
    },
    {
      "sent": "Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 United States $ 9,041 $ 9,201 (1.7) % (1.7) % International 3,269 3,024 8.1 % 11.6 % Net revenues $ 12,310 $ 12,225 0.7 % 1.6 % 2024 Form 10-Q | 31 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Immunology Humira United States $ 1,771 $ 2,948 (39.9) % (39.9) % International 499 593 (15.8) % (11.6) % Total $ 2,270 $ 3,541 (35.9) % (35.2) % Skyrizi United States $ 1,656 $ 1,139 45.3 % 45.3 % International 352 221 59.4 % 61.6 % Total $ 2,008 $ 1,360 47.6 % 48.0 % Rinvoq United States $ 725 $ 449 61.4 % 61.4 % International 368 237 55.3 % 62.8 % Total $ 1,093 $ 686 59.3 % 61.9 % Oncology Imbruvica United States $ 610 $ 638 (4.3) % (4.3) % Collaboration revenues 228 240 (5.1) % (5.1) % Total $ 838 $ 878 (4.5) % (4.5) % Venclexta United States $ 281 $ 265 6.2 % 6.2 % International 333 273 21.9 % 26.1 % Total $ 614 $ 538 14.2 % 16.3 % Elahere (a) United States $ 64 $ \u2014 n/m n/m Epkinly Collaboration revenues $ 22 $ \u2014 n/m n/m International 5 \u2014 n/m n/m Total $ 27 $ \u2014 n/m n/m Aesthetics Botox Cosmetic United States $ 389 $ 409 (4.9) % (4.9) % International 244 250 (2.2) % 1.2 % Total $ 633 $ 659 (3.9) % (2.6) % Juvederm Collection United States $ 106 $ 122 (13.2) % (13.2) % International 191 233 (18.1) % (14.0) % Total $ 297 $ 355 (16.4) % (13.7) % Other Aesthetics United States $ 281 $ 246 13.7 % 13.7 % International 38 40 (3.7) % 1.2 % Total $ 319 $ 286 11.3 % 12.0 % Neuroscience Botox Therapeutic United States $ 611 $ 587 4.1 % 4.1 % International 137 132 3.9 % 6.3 % Total $ 748 $ 719 4.1 % 4.5 % Vraylar United States $ 692 $ 560 23.5 % 23.5 % International 2 1 >100.0 % >100.0 % Total $ 694 $ 561 23.6 % 23.6 % Duodopa United States $ 25 $ 25 (2.6) % (2.6) % International 90 93 (2.7) % (3.7) % Total $ 115 $ 118 (2.7) % (3.5) % Ubrelvy United States $ 197 $ 150 31.5 % 31.5 % International 6 2 >100.0 % >100.0 % Total $ 203 $ 152 33.8 % 33.8 % Qulipta United States $ 128 $ 66 94.5 % 94.5 % International 3 \u2014 >100.0 % >100.0 % Total $ 131 $ 66 97.7 % 97.7 % 2024 Form 10-Q | 32 Three months ended Mar\ns:              (i) $1.6\u00a0billion related to the amortization of intangible assets; (ii) $643\u00a0million for the change in fair value of contingent 2024 Form 10-Q | 28 consideration liabilities; and (iii) $486\u00a0million of acquisition and integration expenses.",
      "score": 0.9913
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.",
      "score": -0.7506
    },
    {
      "sent": "AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud.",
      "score": -0.7269
    }
  ],
  "forward_snippets": [
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "ImmunoGen's oncology portfolio includes its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors.",
    "The combination accelerates AbbVie\u2019s entry into the solid tumor space and strengthens its oncology pipeline.",
    "Some of the more significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product, the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, competitive trends impacting the asset and each cash flow stream, as\nguidance on its consolidated financial statements."
  ],
  "curated_text": "Symbol: ABBV. Year: 2024. Period: Q3. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 United States $ 9,041 $ 9,201 (1.7) % (1.7) % International 3,269 3,024 8.1 % 11.6 % Net revenues $ 12,310 $ 12,225 0.7 % 1.6 % 2024 Form 10-Q | 31 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Immunology Humira United States $ 1,771 $ 2,948 (39.9) % (39.9) % International 499 593 (15.8) % (11.6) % Total $ 2,270 $ 3,541 (35.9) % (35.2) % Skyrizi United States $ 1,656 $ 1,139 45.3 % 45.3 % International 352 221 59.4 % 61.6 % Total $ 2,008 $ 1,360 47.6 % 48.0 % Rinvoq United States $ 725 $ 449 61.4 % 61.4 % International 368 237 55.3 % 62.8 % Total $ 1,093 $ 686 59.3 % 61.9 % Oncology Imbruvica United States $ 610 $ 638 (4.3) % (4.3) % Collaboration revenues 228 240 (5.1) % (5.1) % Total $ 838 $ 878 (4.5) % (4.5) % Venclexta United States $ 281 $ 265 6.2 % 6.2 % International 333 273 21.9 % 26.1 % Total $ 614 $ 538 14.2 % 16.3 % Elahere (a) United States $ 64 $ \u2014 n/m n/m Epkinly Collaboration revenues $ 22 $ \u2014 n/m n/m International 5 \u2014 n/m n/m Total $ 27 $ \u2014 n/m n/m Aesthetics Botox Cosmetic United States $ 389 $ 409 (4.9) % (4.9) % International 244 250 (2.2) % 1.2 % Total $ 633 $ 659 (3.9) % (2.6) % Juvederm Collection United States $ 106 $ 122 (13.2) % (13.2) % International 191 233 (18.1) % (14.0) % Total $ 297 $ 355 (16.4) % (13.7) % Other Aesthetics United States $ 281 $ 246 13.7 % 13.7 % International 38 40 (3.7) % 1.2 % Total $ 319 $ 286 11.3 % 12.0 % Neuroscience Botox Therapeutic United States $ 611 $ 587 4.1 % 4.1 % International 137 132 3.9 % 6.3 % Total $ 748 $ 719 4.1 % 4.5 % Vraylar United States $ 692 $ 560 23.5 % 23.5 % International 2 1 >100.0 % >100.0 % Total $ 694 $ 561 23.6 % 23.6 % Duodopa United States $ 25 $ 25 (2.6) % (2.6) % International 90 93 (2.7) % (3.7) % Total $ 115 $ 118 (2.7) % (3.5) % Ubrelvy United States $ 197 $ 150 31.5 % 31.5 % International 6 2 >100.0 % >100.0 % Total $ 203 $ 152 33.8 % 33.8 % Qulipta United States $ 128 $ 66 94.5 % 94.5 % International 3 \u2014 >100.0 % >100.0 % Total $ 131 $ 66 97.7 % 97.7 % 2024 Form 10-Q | 32 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Other Neuroscience United States $ 61 $ 75 (18.5) % (18.5) % International 13 4 >100.0 % >100.0 % Total $ 74 $ 79 (6.9) % (6.7) % Eye Care Ozurdex United States $ 34 $ 39 (13.7) % (13.7) % International 97 76 27.9 % 29.3 % Total $ 131 $ 115 13.7 % 14.6 % Lumigan/Ganfort United States $ 29 $ 63 (55.0) % (55.0) % International 62 67 (7.6) % (6.4) % Total $ 91 $ 130 (30.5) % (29.9) % Alphagan/Combigan United States $ 15 $ 28 (47.0) % (47.0) % International 44 43 1.9 % 6.9 % Total $ 59 $ 71 (17.7) % (14.7) % Restasis United States $ 44 $ 79 (44.1) % (44.1) % International 13 13 (1.4) % 4.1 % Total $ 57 $ 92 (38.1) % (37.3) % Other Eye Care United States $ 105 $ 110 (4.8) % (4.8) % International 95 90 5.9 % 9.3 % Total $ 200 $ 200 \u2014 % 1.5 % Other Key Products Mavyret United States $ 144 $ 171 (15.8) % (15.8) % International 205 193 6.2 % 9.0 % Total $ 349 $ 364 (4.1) % (2.6) % Creon United States $ 285 $ 305 (6.6) % (6.6) % Linzess/Constella United States $ 257 $ 251 2.5 % 2.5 % International 9 8 9.2 % 6.8 % Total $ 266 $ 259 2.8 % 2.7 % All other $ 744 $ 691 8.2 % 9.9 % Total net revenues $ 12,310 $ 12,225 0.7 % 1.6 % n/m \u2013 Not meaningful (a) Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024. Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 United States $ 9,041 $ 9,201 (1.7) % (1.7) % International 3,269 3,024 8.1 % 11.6 % Net revenues $ 12,310 $ 12,225 0.7 % 1.6 % 2024 Form 10-Q | 31 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Immunology Humira United States $ 1,771 $ 2,948 (39.9) % (39.9) % International 499 593 (15.8) % (11.6) % Total $ 2,270 $ 3,541 (35.9) % (35.2) % Skyrizi United States $ 1,656 $ 1,139 45.3 % 45.3 % International 352 221 59.4 % 61.6 % Total $ 2,008 $ 1,360 47.6 % 48.0 % Rinvoq United States $ 725 $ 449 61.4 % 61.4 % International 368 237 55.3 % 62.8 % Total $ 1,093 $ 686 59.3 % 61.9 % Oncology Imbruvica United States $ 610 $ 638 (4.3) % (4.3) % Collaboration revenues 228 240 (5.1) % (5.1) % Total $ 838 $ 878 (4.5) % (4.5) % Venclexta United States $ 281 $ 265 6.2 % 6.2 % International 333 273 21.9 % 26.1 % Total $ 614 $ 538 14.2 % 16.3 % Elahere (a) United States $ 64 $ \u2014 n/m n/m Epkinly Collaboration revenues $ 22 $ \u2014 n/m n/m International 5 \u2014 n/m n/m Total $ 27 $ \u2014 n/m n/m Aesthetics Botox Cosmetic United States $ 389 $ 409 (4.9) % (4.9) % International 244 250 (2.2) % 1.2 % Total $ 633 $ 659 (3.9) % (2.6) % Juvederm Collection United States $ 106 $ 122 (13.2) % (13.2) % International 191 233 (18.1) % (14.0) % Total $ 297 $ 355 (16.4) % (13.7) % Other Aesthetics United States $ 281 $ 246 13.7 % 13.7 % International 38 40 (3.7) % 1.2 % Total $ 319 $ 286 11.3 % 12.0 % Neuroscience Botox Therapeutic United States $ 611 $ 587 4.1 % 4.1 % International 137 132 3.9 % 6.3 % Total $ 748 $ 719 4.1 % 4.5 % Vraylar United States $ 692 $ 560 23.5 % 23.5 % International 2 1 >100.0 % >100.0 % Total $ 694 $ 561 23.6 % 23.6 % Duodopa United States $ 25 $ 25 (2.6) % (2.6) % International 90 93 (2.7) % (3.7) % Total $ 115 $ 118 (2.7) % (3.5) % Ubrelvy United States $ 197 $ 150 31.5 % 31.5 % International 6 2 >100.0 % >100.0 % Total $ 203 $ 152 33.8 % 33.8 % Qulipta United States $ 128 $ 66 94.5 % 94.5 % International 3 \u2014 >100.0 % >100.0 % Total $ 131 $ 66 97.7 % 97.7 % 2024 Form 10-Q | 32 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Other Neuroscience United States $ 61 $ 75 (18.5) % (18.5) % International 13 4 >100.0 % >100.0 % Total $ 74 $ 79 (6.9) % (6.7) % Eye Care Ozurdex United States $ 34 $ 39 (13.7) % (13.7) % International 97 76 27.9 % 29.3 % Total $ 131 $ 115 13.7 % 14.6 % Lumigan/Ganfort United States $ 29 $ 63 (55.0) % (55.0) % International 62 67 (7.6) % (6.4\nofibrosis following evaluation of the totality of data from the Phase 3 TRANSFORM-1 trial and recent feedback from regulators. Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 United States $ 9,041 $ 9,201 (1.7) % (1.7) % International 3,269 3,024 8.1 % 11.6 % Net revenues $ 12,310 $ 12,225 0.7 % 1.6 % 2024 Form 10-Q | 31 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 Immunology Humira United States $ 1,771 $ 2,948 (39.9) % (39.9) % International 499 593 (15.8) % (11.6) % Total $ 2,270 $ 3,541 (35.9) % (35.2) % Skyrizi United States $ 1,656 $ 1,139 45.3 % 45.3 % International 352 221 59.4 % 61.6 % Total $ 2,008 $ 1,360 47.6 % 48.0 % Rinvoq United States $ 725 $ 449 61.4 % 61.4 % International 368 237 55.3 % 62.8 % Total $ 1,093 $ 686 59.3 % 61.9 % Oncology Imbruvica United States $ 610 $ 638 (4.3) % (4.3) % Collaboration revenues 228 240 (5.1) % (5.1) % Total $ 838 $ 878 (4.5) % (4.5) % Venclexta United States $ 281 $ 265 6.2 % 6.2 % International 333 273 21.9 % 26.1 % Total $ 614 $ 538 14.2 % 16.3 % Elahere (a) United States $ 64 $ \u2014 n/m n/m Epkinly Collaboration revenues $ 22 $ \u2014 n/m n/m International 5 \u2014 n/m n/m Total $ 27 $ \u2014 n/m n/m Aesthetics Botox Cosmetic United States $ 389 $ 409 (4.9) % (4.9) % International 244 250 (2.2) % 1.2 % Total $ 633 $ 659 (3.9) % (2.6) % Juvederm Collection United States $ 106 $ 122 (13.2) % (13.2) % International 191 233 (18.1) % (14.0) % Total $ 297 $ 355 (16.4) % (13.7) % Other Aesthetics United States $ 281 $ 246 13.7 % 13.7 % International 38 40 (3.7) % 1.2 % Total $ 319 $ 286 11.3 % 12.0 % Neuroscience Botox Therapeutic United States $ 611 $ 587 4.1 % 4.1 % International 137 132 3.9 % 6.3 % Total $ 748 $ 719 4.1 % 4.5 % Vraylar United States $ 692 $ 560 23.5 % 23.5 % International 2 1 >100.0 % >100.0 % Total $ 694 $ 561 23.6 % 23.6 % Duodopa United States $ 25 $ 25 (2.6) % (2.6) % International 90 93 (2.7) % (3.7) % Total $ 115 $ 118 (2.7) % (3.5) % Ubrelvy United States $ 197 $ 150 31.5 % 31.5 % International 6 2 >100.0 % >100.0 % Total $ 203 $ 152 33.8 % 33.8 % Qulipta United States $ 128 $ 66 94.5 % 94.5 % International 3 \u2014 >100.0 % >100.0 % Total $ 131 $ 66 97.7 % 97.7 % 2024 Form 10-Q | 32 Three months ended Mar\ns:              (i) $1.6\u00a0billion related to the amortization of intangible assets; (ii) $643\u00a0million for the change in fair value of contingent 2024 Form 10-Q | 28 consideration liabilities; and (iii) $486\u00a0million of acquisition and integration expenses. Top negative sentences: Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. Forward-looking snippets: AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. ImmunoGen's oncology portfolio includes its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors. The combination accelerates AbbVie\u2019s entry into the solid tumor space and strengthens its oncology pipeline. Some of the more significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product, the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, competitive trends impacting the asset and each cash flow stream, as\nguidance on its consolidated financial statements."
}